Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | De-escalating chemo-radiotherapy in locally advanced HPV+ oropharynx cancer

Marshall R. Posner, MD, The Tisch Cancer Institute, New York, NY, describes an analysis of patients with locally advanced human papillomavirus (HPV)-positive oropharynx cancer (OPC) from two different trials (NCT02945631, NCT01706939) who received induction chemotherapy followed by de-escalated chemoradiotherapy. 32 patients, who had risk factors such as extranodal extensions, T4 lesions, or N2c disease were enrolled for analysis and had a favorable overall response (OS) and progression-free survival (PFS), with no treatment-related mortalities. The results highlight the efficacy of radiotherapy de-escalation for patients with locally advanced HPV positive OPC. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.


Marshall R. Posner, MD has received consultancy feed from Merck (DMC), Kura (ad board), Hookipa (ad board), BioNtech (ad board), and Naveris (ad board).